Key facts
- This page summarizes Todd A. Trapp's Form 4 filing for ABIOMED INC.
- 1 reported transaction and 3 derivative rows are listed below.
- Accepted by SEC: 06 Apr 2022, 16:26.
Todd A. Trapp - 04 Apr 2022 Form 4 Insider Report for ABIOMED INC
- Reporting relationship
- VICE PRESIDENT, CFO
- Issuer ticker
- N/A
- Reported as of
- 04 Apr 2022
- Net transaction value
- -$333,000
- SEC form
- 4
- Accepted by SEC
- 06 Apr 2022, 16:26:18 UTC
- Prior SEC filing
- 07 Jan 2022
- Next SEC filing
- 27 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marc A. Began (by power of attorney)
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Todd A. Trapp filed Form 4 for ABIOMED INC on 06 Apr 2022.
Change
- Previous filing in this sequence was filed on 07 Jan 2022.
- Current net transaction value: -$333,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NASD
transaction
Common Stock, $0.01 par value
Sale
- Transaction value
- $333,000
- Shares
- -1,000
- Change %
- -7.1%
- Price
- $333.00*
- Shares after
- 13,063
- Date
- 04 Apr 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NASD
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,000
- Date
- 04 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 0
- Exercise price
- $266.39
- Footnotes
- F3, F4
NASD
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,530
- Date
- 04 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 0
- Exercise price
- $223.90
- Footnotes
- F3, F4
NASD
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,737
- Date
- 04 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 0
- Exercise price
- $283.88
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Sale of common stock pursuant to reporting owner's 10b5-1 plan.
Footnote F2
This price represents the sale price of the transactions on the reported date at $333.00. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
Footnote F3
Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan.
Footnote F4
These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.